Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Types

    ... divides MDS in to five subtypes based on percentage of blasts in the bone marrow and the peripheral blood. It is now used ... FAB-type % blasts in blood % blasts in bone marrow ...

    Topic section last updated 07/20/2018 - 5:15pm.

  2. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

    ... in myelodysplastic syndromes (MDS), clonal blasts gain a more aggressive nature, whereas nonclonal immune cells ... and tumor necrosis factor-alpha (TNFalpha) on MDS blasts. This induction was associated with the activation of nuclear ... inhibitor, pyrrolidine dithiocarbamate (PDTC). B7-H1(+) MDS blasts had greater intrinsic proliferative capacity than B7-H1(-) MDS blasts ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

    ... with refractory anemia with excess blasts -1, -2, or, -t myelodysplastic syndromes (MDS) following ... addition, 15 patients achieved stabilization of bone marrow blasts. One patient with a complete bone marrow response also achieved a ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... 20%, RAEB-2 in 54%, and RAEB-t (AML with 21%-30% marrow blasts ) in 22%. Cytogenetic risk was good in 31%, intermediate in 17%, and ... arabinoside treatment (P = .009), bone marrow blasts > 15% (P = .004), and abnormal karyotype (P = .03) independently ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... in many countries for the treatment of AML with 20%-30% blasts and multilineage dysplasia according to the World Health ... of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. Oral administration of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine.

    ... definition of acute myeloid leukemia (AML) to ≥ 20% blasts , the International Working Group (IWG) response criteria for ... with myelodysplastic syndrome (MDS) with baseline marrow blasts ≥ 20% and < 30% (RAEB-t group) and < 20% (MDS group) were compared. ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. The Myelodysplastic Syndromes (MDS): A personal recollection of four decades of classification and prognostic scoring systems.

    ... namely refractory anemia with excess blasts (RAEB) and chronic myelomonocytic leukemia (CMML). Subsequent ... of the degrees of morphologic dysplasia and percentage of blasts have enhanced the classification. Several prognostic scoring systems ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... analysis of peripheral cytopenias, percentage of blasts in the bone marrow and cytogenetic characteristics. The most ... based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic profile. Goals of therapy are different ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... include analysis of peripheral cytopenias, percentage of blasts in the bone marrow and cytogenetic characteristics. The most ... based on risk, transfusion needs, percent of bone marrow blasts, and, more recently, cytogenetic profile. Goals of therapy are different ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Expression of DLK1 Gene in the Bone Marrow Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significance.

    ... positive correlation with the proportion of bone marrow blasts (r=0.467, P<0.05). Moreover, DLK1 mRNA expression was significantly ... positively correlated with the proportion of the bone marrow blasts. A high expression of DLK1 gene suggested a higher malignant clone ...

    Research Article last updated 07/20/2018 - 5:15pm.